TVGN

Tevogen Bio Holdings Inc. (TVGN) - 10-K Summary

Business Context and Reporting Period

Company: Tevogen Bio Holdings Inc.
Reporting Period: Fiscal year ended December 31, 2025.
Business Model: Clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies (ExacTcell technology) for infectious diseases, cancer, and neurological disorders.
Key Asset: TVGN 489, an allogeneic cytotoxic CD8+ T cell therapy for COVID-19 and Long COVID. The company completed a Phase 1 proof-of-concept trial in January 2023 with positive safety and efficacy signals. No products are currently approved for commercial sale.

Key Financial Metrics (Year Ended Dec 31, 2025)

Material Changes vs. Prior Period

• Reduced Operating Expenses: Total operating expenses decreased by approximately $27.5 million (51%) from 2024 to 2025. This was primarily driven by a significant reduction in non-cash stock-based compensation expense ($24.5 million decrease) and lower legal/professional fees.
• Increased Net Loss: Despite lower operating expenses, the net loss increased from $13.7 million to $26.3 million. The 2024 period included a one-time non-cash gain of $48.5 million from the change in fair value of convertible promissory notes, which was absent in 2025.
• Liquidity Position: Cash on hand decreased from $1.3 million to $0.6 million. However, the company has drawn an additional $3.4 million under its Loan Agreement and received $3.0 million in grants during 2025.
• Capital Structure: The company completed a 1-for-50 reverse stock split effective March 6, 2026, to regain compliance with Nasdaq listing requirements.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash ($0.6M), proceeds from the Sales Agreement ($0.9M post-year-end), available Loan Agreement capacity ($18.0M), and a committed $7.0 million grant from KRHP LLC are sufficient to fund operations for at least the next 12 months.
• Development Plan: The company plans to launch a pivotal trial of TVGN 489 in COVID-19 patients with B cell malignancies. It is also exploring a Phase 2 trial for Long COVID. The company does not plan to initiate new clinical trials until additional funding is secured.
• Key Risks:
  • Capital Needs: The company has a history of significant losses and will require substantial additional financing to achieve business objectives. Failure to secure funding could force delays or termination of R&D.
  • Regulatory Uncertainty: There is no assurance that the FDA will permit a transition from Phase 1 directly to pivotal trials or that TVGN 489 will receive regulatory approval.
  • Internal Controls: The company identified a material weakness in internal control over financial reporting related to risk assessment processes, though one weakness regarding segregation of duties was remediated in 2025.
  • Market Volatility: The stock price has been volatile, and the company previously failed to meet Nasdaq's minimum bid price requirement, necessitating the reverse stock split.

Investor Verification Checklist

• Grant Funding Status: Verify the receipt and terms of the remaining $7.0 million grant commitment from KRHP LLC, as this is critical to the 12-month liquidity runway.
• Loan Agreement Terms: Review the specific terms of the Loan Agreement with The Patel Family, including interest rates, maturity dates, and the conditions for the $14 million purchase option.
• Regulatory Pathway: Confirm the FDA's stance on the proposed pivotal trial design for TVGN 489, specifically whether a Phase 2 trial is required before a pivotal Phase 3.
• Internal Control Remediation: Monitor the progress of remediation for the remaining material weakness regarding risk assessment processes in internal controls.
• Preferred Stock Obligations: Assess the impact of cumulative dividends on Series A and Series C Preferred Stock on future cash flow and dilution.